Pipeline
The Science
About us
Investors

Hit enter to search or ESC to close

Prana Biotechnology Investor Presentation

June 27, 2018August 16, 2022 Alterity Therapeutics

1_Prana Biotechnology Investor Presentation_2018-0627 final

2018

Post navigation

Prana to commence Phase 1 clinical trial of PBT434 for treatment of parkinsonian diseases

First volunteers dosed in Phase I clinical trial of PBT434, Prana’s lead therapy for parkinsonian diseases

Related Posts

Prana Appoints David Stamler as Chief Medical Officer to Lead Clinical Development

June 5, 2017August 16, 2022

The Lancet Neurology publishes Prana’s Huntington’s Disease Trial

November 18, 2014August 16, 2022

Alterity Therapeutics Announces Successful Completion of Phase 1 Clinical Trial

July 29, 2019August 16, 2022

Recent Posts

Alterity Therapeutics Issues Shareholder Newsletter Highlighting Pipeline Advances and Key Upcoming Milestones
Alterity Therapeutics Completes Last Patient Visit in ATH434-201 Phase 2 Clinical Trial in Early-Stage Multiple System Atrophy
Chairman’s Address 2024 Annual General Meeting
AGM 2024 Presentation
Alterity Therapeutics Announces Presentation on Tracking the Progression of Multiple System Atrophy at International Symposium

Recent Comments

Archives

Archives

Categories

ASX Announcements
Chairman's Address
Investor Announcement

Tags

2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023

About us

We exist to create an alternate future for people living with neurodegenerative diseases. An alternate, healthier life. We’re here to disrupt the trajectory the world has come to accept for people with these diseases.
Improving lives.

LinkedIn
Facebook
X

Pipeline
The Science
About us
Investors
News

Careers
Privacy Policy

Copyright © Alterity Therapeutics. ABN 37 080 699 065